How Big Players and Startups Share the Catheter Market Stage

Catheters are among the most widely used medical devices in modern care. They are used in cardiac interventions, neurovascular procedures, long-term urological management, and everyday IV therapy. As chronic disease rates climb and minimally invasive procedures become standard, demand for these devices keeps rising. Here is what Grand View Research's latest analysis says about where the market is heading.

Market Valuation & Growth Projections

The global catheter market was valued at USD 61.9 billion in 2025. It is estimated at USD 65.9 billion in 2026 and is projected to reach USD 103.9 billion by 2033, a CAGR of 6.7% over 2026-2033.

By product, cardiovascular catheters led in 2025 with about 28.3% of revenue. This is driven by rising cardiac disease and the growing number of interventional procedures. Specialty catheters are expected to grow fastest, supported by demand for minimally invasive treatments and a steady flow of regulatory approvals. Specialty devices also tend to use smoother surfaces and lower-friction materials, which improve comfort for patients who need long-term catheterization.

Geographic & End-Use Dynamics

North America was the largest regional market in 2025 with a 29.6% revenue share, and the U.S. is its biggest contributor. The region benefits from an aging population, a high burden of chronic illness, strong healthcare spending, and the presence of major manufacturers such as Teleflex, Medtronic, and Boston Scientific.

Europe is set for significant growth as its population ages. Eurostat figures show more than one-fifth of the EU population is aged 65 or older. Urological conditions are a notable driver in the UK, where an estimated 7 million people live with urinary incontinence.

Asia Pacific is the fastest-growing region. It has a large patient pool, better medical infrastructure, wider insurance coverage, and higher surgical volumes. The cardiovascular outlook underlines the opportunity. A 2024 Lancet study projects that CVD cases in Asia will reach 729.5 million by 2050, more than double the 2025 level. India stands out for manufacturing momentum, including a 2024 MoU between Lubrizol and Polyhose to produce medical tubing locally for neurovascular and cardiovascular catheters. China's expanding healthcare system and Saudi Arabia's Vision 2030 investments are also widening access to catheter technologies.

By end use, hospital stores held the largest share (53.3%) in 2025. Hospitals need immediate access to a wide range of catheters under strict storage and dispensing rules. Retail stores are projected to grow fastest as e-commerce platforms make catheters easier to buy.

Get the Full Picture. This post covers only the highlights. The full report spans 20+ countries and profiles 10+ key players, with segment-level forecasts through 2033. Download a Free Sample Report to preview the data points, trend analysis, and forecasts.

Market Drivers

• Chronic disease burden: Cardiovascular, neurological, and urological conditions are increasing hospitalizations and procedures. UTIs alone affect roughly 250 million people each year, according to a 2024 Lancet study.
• Infection prevention: CDC data indicates that around 75% of hospital-acquired UTIs are linked to urinary catheters, and 15-25% of hospitalized patients receive one. This is pushing demand for antimicrobial and infection-resistant designs. Examples include Bactiguard-coated Foley catheters and CorMedix's FDA-approved DefenCath, which showed up to a 71% reduction in catheter-related bloodstream infection risk in a Phase 3 study.
• Manufacturing innovation and capacity: New materials, such as Junkosha's shrink-tube solution for complex catheter shapes, are improving production efficiency. Companies are also expanding facilities to keep pace with demand.
• Product launches: Recent examples include J&J MedTech's CEREGLIDE 92 neurovascular system and Terumo's R2P NaviCross peripheral support catheter.

Market Restraints
Catheter use carries a real risk of healthcare-associated infections, particularly CAUTIs and CLABSIs. This puts pressure on hospitals and manufacturers to meet tighter safety expectations. Manufacturers must also clear demanding regulatory pathways with the FDA and European authorities before commercialization, which adds time and cost. Both pressures are also pushing innovation, since infection-resistant products and better securement and flushing solutions create room for differentiation.

Competitive Landscape

The market is fragmented, with many device makers across cardiology, urology, and neurology. Key players include Hollister, Medtronic, Boston Scientific, Edwards Lifesciences, Smith Medical, Teleflex, ConvaTec, Cure Medical, Terumo, Cook Medical, and BD. Emerging names such as Flow Medical, S3V Vascular Technologies, and Liquet Medical add further competition.

Companies are competing mainly through:

• Product launches and regulatory approvals, such as Cook Medical's Slip-Cath Beacon hydrophilic angiographic catheter and Radical Catheter Technologies' FDA-cleared 8F neurovascular catheter.
• Acquisitions and partnerships, such as Quasar Medical's 2024 purchase of balloon catheter developer Ridgeback Technologies.
• Geographic expansion, such as Teleflex's rollout of its Arrow pressure injectable midline catheter in the Middle East, Europe, and Africa.
• Coating and material innovation aimed at reducing infection and improving trackability.

Customize This Report to add regions, segments, or data points relevant to your strategy, with 20% free customization.